A-22

Dosage for Aspergillus Flavus must be highly individualized based on the patient's sensitivity level, which is determined by the clinical history and skin test reactivity.

Diagnostic Dosing

• Skin Prick Test: Typically uses a 1:10 or 1:20 w/v concentration. A single drop is applied to the skin, followed by a puncture. Results are read at 15–20 minutes.
• Intradermal Test: If the prick test is negative, an intradermal injection of 0.02 mL to 0.05 mL of a much more dilute solution (e.g., 1:1000 w/v) may be administered.

Immunotherapy Dosing

• Build-up Phase: Treatment usually begins with a very low dose (e.g., 0.1 mL of a 1:100,000 w/v dilution). Injections are given 1–2 times per week, with the dose increasing by 20–50% each time, provided no significant local or systemic reactions occur.
• Maintenance Phase: Once the 'maintenance dose' is reached (typically 0.5 mL of a 1:100 or 1:10 w/v concentration), the interval between injections is increased to every 2–4 weeks.

Aspergillus Flavus extracts are generally considered safe for use in children, provided they are administered by a specialist. Dosing principles for children are similar to those for adults, though some clinicians may use a more conservative build-up schedule. There is no specific age cutoff, but the benefits of immunotherapy must be weighed against the child's ability to tolerate frequent injections and the risk of systemic reactions.

Renal Impairment

No specific dosage adjustments are typically required for renal impairment, as the protein load in an allergenic extract is negligible. However, patients with severe renal disease may be at higher risk if they require epinephrine to treat an accidental systemic reaction.

Hepatic Impairment

No dosage adjustments are necessary for patients with hepatic impairment.

Elderly Patients

Caution is advised in elderly patients, particularly those with underlying cardiovascular disease. The risk-benefit ratio must be carefully evaluated because the elderly may be less able to tolerate the physiological stress of a systemic allergic reaction or the effects of epinephrine used for emergency treatment.

Aspergillus Flavus extracts are for professional use only and should never be self-administered by the patient at home.

• Administration Route: Immunotherapy injections must be given subcutaneously (SQ), usually in the posterior aspect of the upper arm. They must NOT be given intravenously.
• Observation Period: Patients must remain in the medical office for at least 30 minutes following any injection to monitor for signs of anaphylaxis.
• Storage: Vials must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Fungal proteins are heat-labile and will lose potency if left at room temperature for extended periods.

If a dose in the build-up phase is missed, the next dose may need to be reduced depending on the length of the delay.

• Delay of 1 week: Repeat the last dose.
• Delay of 2+ weeks: Reduce the dose by one or more increments according to the clinic's protocol.
• Maintenance Phase: If a maintenance dose is significantly delayed (e.g., >6 weeks), the dose is typically reduced to ensure safety.

An 'overdose' in the context of allergenic extracts usually refers to the administration of a dose higher than the patient's current tolerance level, which can lead to a severe systemic reaction.

• Signs: Rapid onset of hives, swelling of the throat, wheezing, hypotension (low blood pressure), and loss of consciousness.
• Emergency Measures: Immediate administration of Epinephrine (1:1000) intramuscularly, followed by antihistamines, corticosteroids, and supportive care (oxygen, IV fluids). Emergency medical services must be activated.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or skip appointments without medical guidance.

Most patients undergoing treatment with Aspergillus Flavus will experience some form of local reaction. These are generally not dangerous but can be uncomfortable.

• Local Swelling: A 'wheal' or lump at the injection site that may appear immediately or several hours later. It typically resolves within 24 hours.
• Redness (Erythema): Reddening of the skin around the injection site, often accompanied by warmth.
• Itching (Pruritus): Intense itching at the site of the injection or skin test.
• Tenderness: The injection site may feel sore to the touch for a day or two.

• Large Local Reactions: Swelling that exceeds 5–10 cm in diameter. This may require a dose adjustment for the next injection.
• Fatigue: Some patients report feeling unusually tired for several hours after an immunotherapy session.
• Mild Nasal Congestion: A slight increase in hay fever-like symptoms shortly after the injection.

• Generalized Urticaria (Hives): Hives appearing on parts of the body away from the injection site.
• Angioedema: Swelling of the deeper layers of the skin, often around the eyes or lips.
• Persistent Granuloma: A small, firm bump at the injection site that may persist for weeks.

> Warning: Stop taking Aspergillus Flavus and call your doctor immediately or seek emergency care if you experience any of these symptoms of anaphylaxis.

• Difficulty Breathing: Wheezing, chest tightness, or shortness of breath suggesting bronchospasm.
• Throat Tightness: A feeling that the throat is closing, or difficulty swallowing.
• Hypotension: Dizziness, lightheadedness, or fainting due to a sudden drop in blood pressure.
• Rapid or Weak Pulse: Signs of cardiovascular distress.
• Nausea and Vomiting: Systemic allergic reactions can sometimes manifest as acute gastrointestinal distress.
• Cyanosis: Bluish tint to the lips or fingernails, indicating a lack of oxygen.

There are no known long-term 'toxic' effects of Aspergillus Flavus extracts, as they are biological proteins. However, prolonged immunotherapy (3–5 years) is designed to permanently alter the immune system's response. In rare cases, patients may develop 'serum sickness-like' reactions (joint pain, fever, rash) if they are receiving very high doses of foreign proteins, though this is extremely uncommon with modern allergenic extracts.

Aspergillus Flavus extracts carry an FDA-mandated Black Box Warning common to all allergenic extracts:

WARNING: RISK OF SEVERE ALLERGIC REACTIONS

• Allergenic extracts can cause severe life-threatening systemic reactions, including anaphylaxis.
• Do not administer to patients with unstable or severe asthma.
• Observe patients for at least 30 minutes after injection.
• Extracts should only be administered in settings equipped to manage anaphylaxis, including the availability of epinephrine.
• Patients should be informed of the risks and instructed on how to recognize systemic symptoms.

Report any unusual symptoms or reactions to your healthcare provider immediately. Even a large local reaction can sometimes be a precursor to a future systemic reaction.

Aspergillus Flavus allergenic extract is a potent biological substance. Its use is restricted to physicians who are experienced in the diagnosis and treatment of allergic diseases. Patients must be aware that while the goal is to reduce allergy symptoms, the treatment itself involves controlled exposure to the very substance that triggers their allergies.

No FDA black box warnings are unique to Aspergillus Flavus specifically, but it falls under the general black box warning for all Allergenic Extracts. This warning emphasizes the risk of anaphylaxis and the necessity of administration by trained medical personnel in facilities equipped with emergency resuscitation equipment.

• Anaphylaxis Risk: This is the primary concern. Risk is increased if the patient is symptomatic (e.g., having an active asthma flare) at the time of the injection.
• Asthma Status: Patients with severe, unstable, or steroid-dependent asthma are at a significantly higher risk for fatal reactions. Immunotherapy should be withheld if the patient’s peak flow is significantly below their personal best.
• Cardiovascular Disease: Patients with pre-existing heart conditions may be unable to tolerate the physiological stress of a systemic reaction or the compensatory tachycardia (fast heart rate) caused by emergency epinephrine.
• Beta-Blocker Use: Patients taking beta-blockers (e.g., metoprolol, propranolol) may be resistant to the effects of epinephrine, making a systemic reaction much harder to treat.

• Pre-Injection Assessment: The clinician should assess the patient for current allergy symptoms, recent asthma flares, or any new medications.
• Post-Injection Observation: A mandatory 30-minute wait time in the clinic is standard. Some high-risk patients may require longer observation.
• Lung Function: For asthmatic patients, peak flow monitoring before and after injections may be required.
• Skin Test Reactivity: Periodic re-evaluation of skin test sensitivity may be performed to assess the progress of immunotherapy.

Aspergillus Flavus does not typically cause sedation. However, if a patient experiences a systemic reaction or receives epinephrine, they should not drive or operate machinery until they have fully recovered and been cleared by a physician.

While there is no direct chemical interaction between alcohol and Aspergillus Flavus, alcohol consumption can cause vasodilation, which may theoretically increase the rate of allergen absorption or worsen the severity of an allergic reaction. It is generally advised to avoid heavy alcohol use on the day of an injection.

Immunotherapy is typically discontinued after 3 to 5 years of successful maintenance. There is no 'withdrawal' syndrome. However, if treatment is stopped prematurely, the patient's allergy symptoms are likely to return to their baseline level.

> Important: Discuss all your medical conditions, especially asthma and heart problems, with your healthcare provider before starting Aspergillus Flavus.

There are few absolute contraindications for drug combinations, but the following are generally avoided:

• Beta-Adrenergic Blockers: Drugs like propranolol or carvedilol are often considered a contraindication for immunotherapy. The clinical consequence is that if the patient has an anaphylactic reaction, the beta-blocker will prevent epinephrine from working effectively, potentially leading to a fatal outcome.

• ACE Inhibitors: Some studies suggest that patients on ACE inhibitors (e.g., lisinopril) may be at higher risk for more severe systemic reactions to allergenic extracts.
• MAO Inhibitors: These can potentiate the effects of epinephrine, which might be used to treat a reaction, leading to a hypertensive crisis.
• Tricyclic Antidepressants: Similar to MAOIs, these can increase the sensitivity of the cardiovascular system to epinephrine.

• Other Allergenic Extracts: If a patient is receiving multiple extracts (e.g., grass, ragweed, and Aspergillus), the cumulative 'allergic load' may increase the risk of a systemic reaction. These are often mixed into a single vial, but the total protein content must be carefully calculated.
• Antihistamines: While not dangerous, taking antihistamines (e.g., cetirizine, loratadine) before a diagnostic skin test will suppress the wheal and flare reaction, leading to a false-negative result. Antihistamines should be stopped 3–7 days before testing.

• Cross-Reactive Foods: Some patients with Aspergillus mold allergy may show cross-reactivity with certain fermented foods or mushrooms, though this is clinically distinct from the injection therapy.
• High-Fat Meals: There is no evidence that food intake affects the subcutaneous absorption of Aspergillus Flavus extracts.

• St. John's Wort: May theoretically affect the metabolism of medications used to treat allergic reactions, though no direct interaction with the extract exists.
• Licorice Root: May have mild corticosteroid-like effects that could theoretically mask a minor reaction.

• Skin Testing: As mentioned, antihistamines, H2 blockers (e.g., famotidine), and certain antidepressants can interfere with the results of skin tests.
• Total IgE: Immunotherapy may cause a transient rise in total IgE levels before they eventually decline.

For each major interaction, the mechanism is usually pharmacodynamic (affecting the body's response to the drug or the rescue medication) rather than pharmacokinetic (affecting the drug's levels in the blood).

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially any heart or blood pressure medications.

Aspergillus Flavus extracts must NEVER be used in the following circumstances:

• Severe, Unstable Asthma: Patients with a forced expiratory volume (FEV1) consistently below 70% of predicted or those with recent acute exacerbations are at an unacceptably high risk of fatal bronchospasm during immunotherapy.
• Previous Severe Anaphylaxis to this Specific Extract: If a patient has had a near-fatal reaction to Aspergillus Flavus in the past, the risks of continuing immunotherapy usually outweigh the benefits.
• Acute Infection: Injections should not be given during an active febrile illness, as this can lower the threshold for a systemic allergic reaction.

Conditions requiring careful risk-benefit analysis include:

• Beta-Blocker Therapy: As noted, this complicates the treatment of anaphylaxis.
• Autoimmune Disorders: There is a theoretical concern that stimulating the immune system with allergenic extracts could worsen certain autoimmune conditions (e.g., SLE, rheumatoid arthritis), though data are limited.
• Malignancy: Patients with active cancer may have altered immune profiles that make immunotherapy less predictable.
• Severe Atopic Dermatitis: May make the interpretation of skin tests difficult.

Patients allergic to Aspergillus Flavus may also react to other species within the Aspergillus genus (e.g., A. fumigatus, A. niger) or even other molds like Penicillium. This is due to shared protein structures (homologous allergens). If a patient is known to be extremely sensitive to one mold, the clinician will exercise extra caution when testing or treating with Aspergillus Flavus.

> Important: Your healthcare provider will evaluate your complete medical history, including your lung function and current medications, before prescribing Aspergillus Flavus.

Aspergillus Flavus is classified as Pregnancy Category C. This means there are no adequate and well-controlled studies in pregnant women.

• Risks: The primary risk during pregnancy is not the extract itself, but the potential for a systemic reaction (anaphylaxis) in the mother, which can cause fetal hypoxia (lack of oxygen to the baby).
• Management: It is generally recommended not to start new immunotherapy or increase doses during pregnancy. However, if a woman is already on a stable maintenance dose and is tolerating it well, the treatment may be continued at that dose.

It is not known whether the components of Aspergillus Flavus extract are excreted in human milk. However, because the allergens are proteins that are digested in the infant's gut, the risk to a nursing infant is considered extremely low. The decision to continue immunotherapy while breastfeeding should be a joint decision between the mother and her physician.

Immunotherapy with Aspergillus Flavus is effective in children for treating allergic rhinitis and asthma.

• Age: It is rarely started in children under age 5 due to the difficulty of communication regarding systemic symptoms and the trauma of frequent injections.
• Growth: There is no evidence that allergenic extracts affect growth or development.

Patients over age 65 require careful screening.

• Cardiovascular Risk: The elderly are more likely to have undiagnosed coronary artery disease, making them poor candidates for the physiological stress of a reaction.
• Polypharmacy: The high prevalence of beta-blocker and ACE inhibitor use in this population adds another layer of risk.

There are no specific guidelines for renal impairment. Since the extract is administered in minute quantities and consists of naturally occurring proteins, it does not accumulate in the blood in the way that synthetic drugs do.

No adjustments are needed for patients with liver disease. The metabolism of these proteins occurs via general proteolytic pathways throughout the body, not solely in the liver.

> Important: Special populations require individualized medical assessment. Always inform your allergist if you become pregnant or develop new health problems.

Aspergillus Flavus extract acts as an immunomodulator. In the diagnostic phase, it utilizes the Type I Hypersensitivity mechanism, where allergen-specific IgE on mast cells triggers mediator release. In the therapeutic phase, it induces Immune Tolerance. This involves:

1. 1T-cell Deviation: Shifting the response from Th2 (which produces IL-4, IL-5, and IL-13) to Th1 (which produces IFN-gamma).
2. 2T-Regulatory Cell Induction: Increasing IL-10 and TGF-beta, which suppress allergic inflammation.
3. 3B-cell Switching: Promoting the production of IgG4, which acts as a 'blocking antibody' to prevent IgE from binding to the allergen.

• Onset of Action: For skin testing, the effect is immediate (15–20 minutes). For immunotherapy, clinical improvement typically takes 6 to 12 months of consistent treatment.
• Duration of Effect: A full course of immunotherapy (3–5 years) can provide symptom relief that lasts for several years after the treatment is stopped.
• Tolerance: Unlike many drugs, 'tolerance' here is the desired therapeutic goal (the body becoming 'tolerant' to the mold).

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Subcutaneous/Local) |

| Protein Binding | N/A (Degraded by proteases) |

| Half-life | Minutes to hours (Proteins); Years (Immunologic memory) |

| Tmax | 15-30 minutes (Local reaction) |

| Metabolism | Local and systemic proteolytic degradation |

| Excretion | Renal (as amino acids/peptides) |

• Composition: A complex mixture of proteins, glycoproteins, and polysaccharides derived from Aspergillus flavus cultures.
• Molecular Weight: Ranges from 10 kDa to over 100 kDa for various allergenic fractions (e.g., Asp f 1, Asp f 2).
• Solubility: Soluble in aqueous buffers; often stabilized with 50% glycerin or human serum albumin.

Aspergillus Flavus is a Non-Standardized Fungal Allergenic Extract. It is grouped with other mold extracts like Alternaria, Cladosporium, and Penicillium. While it shares some EPC classifications with Adrenergic Agonists in certain databases, this is likely due to its biochemical complexity or historical regulatory filing categories rather than its primary clinical use.